Novartis CEO Warns US Biotech Investment Curbs Could Slow Drug Development
Novartis CEO Vas Narasimhan said that the United States’ proposed curbs on biotech investments in China could impede the development of new drugs, highlighting a potential risk for the pharmaceutical industry.